5 Must Knows for US Biotechs Looking to run Early Access Programs in France

White papers - 26 May 2023

Pharmablue / White papers / 5 Must Knows for US Biotechs Looking to run Early Access Programs in France

5 Must Knows for US Biotechs Looking to run Early Access Programs in France

 

Download the 5 must-knows for US Biotechs looking to run Early Access Programs in France:

 

  • Regulatory Constraints – The Exploitant
  • Financial and Resources Constraints
  • Administrative and Management Constraints
  • New Regulations in 2021
  • French fast evolving regulations

 

 

Download the
White Paper


    PharmaBlue undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
    Any inquiries, correction or declaration of event related to personal data processed should be sent to: our contact page
    Learn more

     

     

    Thank you for your interest in PharmaBlue.

    You can download the file by clicking on “Download”.

    Download